Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pdi Pharm Development International AG has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The portfolio's active prosecution involves a distinct examiner and 1 distinct art unit. This indicates that the company's current legal efforts at the patent office are highly centralized.
The busiest examiner, CONNORS, ALEXANDRA F, is responsible for the pending office action. Since there is only the pending office action in the entire portfolio, this examiner manages all current examination tasks. The limitation to 1 distinct art unit further highlights the specific technical focus of the pending application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CONNORS, ALEXANDRA F | 1 | 23.9% | +45.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16328853 | Provision of a Therapeutically Active Cell Product | CONNORS, ALEXANDRA F | 10d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16328853 | Provision of a Therapeutically Active Cell Product | CONNORS, ALEXANDRA F | 10d overdue |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16328853 | Provision of a Therapeutically Active Cell Product | CONNORS, ALEXANDRA F | 1634 | §103 | Non-Final OA | 10d overdue | Pending | Feb 27, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial